Kochiadakis 2004a.
Methods | RCT Single‐blind Loss to follow‐up reported: no |
|
Participants | Any documented symptomatic previous or persistent AF. Type: paroxysmal or recent onset 63%, persistent 37% (mean duration: 8 months). n = 146 Men: 49% Age (mean): 63 (SD 9) years Structural heart disease: 38%. LAD: 43 mm. LVEF: 53% |
|
Interventions | Amiodarone 200 mg/day vs propafenone 450 mg/day Method of AF cardioversion: both pharmacological and electrical, % NS Warfarin discretionary |
|
Outcomes | At 12 and 24 months: Mortality Proarrhythmia Adverse effects AF recurrence |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Method of randomisation not described. |
Allocation concealment (selection bias) | Unclear risk | Method of concealment not described. |
Blinding (performance bias and detection bias) All outcomes | High risk | Single‐blind study. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Lost to follow‐up are not clearly described. |
Selective reporting (reporting bias) | Low risk | All prespecified outcomes were reported in the prespecified way. All expected outcomes of interest were reported. |
Other bias | Low risk | No other bias apparent. |